Hereditary hemochromatosis affects roughly 1 in 300 to 500 people of European descent, making it the most common inherited metabolic disorder in White populations. But those numbers tell only part of the story. The gap between carrying the genetic mutation and actually getting sick is enormous, which is why hemochromatosis is simultaneously one of the most common genetic conditions and one of the most underdiagnosed.
Overall Prevalence by Ancestry
Type 1 hemochromatosis, the classic form caused by mutations in the HFE gene, is primarily a condition of Northern European descent. Rates are highest among people of Celtic or Scandinavian origin, and prevalence is roughly the same across Europe, Australia, and other Western countries with large populations of European ancestry. The other forms of hereditary hemochromatosis (types 2, 3, and 4) occur worldwide but are considerably rarer.
To put the 1-in-300-to-500 figure in perspective: hemochromatosis is more common than cystic fibrosis, which affects about 1 in 2,500 White Americans. In populations with heavy Celtic ancestry, such as Ireland, the carrier rate for a single copy of the main mutation can be as high as 1 in 5. Most carriers never develop iron overload, though. You need two copies of the mutation (one from each parent) to be at meaningful risk.
Carrying the Gene vs. Getting Sick
This is where hemochromatosis statistics get complicated. Having two copies of the C282Y mutation (the primary genetic variant) does not guarantee you will develop symptoms. The overall rate of clinically significant iron overload among men with this genotype is estimated at about 28%. For severe liver disease specifically, the lifetime risk for men is approximately 9%, or roughly 1 in 10 male carriers. Women with the same genotype develop serious complications far less often.
The term researchers use for this gap is “clinical penetrance,” and it explains a long-running debate in medicine about whether population-wide screening for hemochromatosis makes sense. Millions of people carry two copies of the mutation but will never store enough iron to damage their organs. Diet, alcohol use, other genetic factors, and biological sex all influence whether the mutation leads to disease.
Why Women Are Diagnosed Later
Men typically develop symptoms after age 40. Women are more likely to notice problems after age 60, or specifically after menopause. The reason is straightforward: menstruation and pregnancy both remove iron from the body. For decades, these regular losses counterbalance the excess absorption caused by the mutation. After menopause or a hysterectomy, that protective effect disappears and iron begins to accumulate more quickly.
This timing difference means hemochromatosis has historically been seen as a “men’s disease,” which contributes to underdiagnosis in women. Women may also present with less specific symptoms like fatigue and joint pain, which are easily attributed to aging or menopause itself.
What Happens Without Treatment
Before modern genetic testing existed, hemochromatosis was usually caught only after severe organ damage had already occurred. Through the mid-20th century, about 80% of patients diagnosed with the condition also had diabetes, because doctors weren’t looking for iron overload until it had already destroyed enough pancreatic tissue to disrupt blood sugar control. The old medical term “bronze diabetes” reflects how late these diagnoses came: patients had both the skin darkening and the diabetes that signal advanced iron deposition.
Today the picture is very different. In one study of men with two copies of the C282Y mutation and significantly elevated iron stores, about 40% had cirrhosis and 14% had diabetes. But even among men with the same genotype and only mildly elevated iron, diabetes prevalence was similar (around 15%), suggesting that iron overload is not the only factor driving diabetes risk in this population.
The most serious long-term risks of untreated hemochromatosis include cirrhosis, primary liver cancer, diabetes, heart muscle damage, and hormonal disruptions. Liver cancer risk is particularly elevated once cirrhosis has developed. Notably, pancreatic cancer risk does not appear to be increased.
How Iron Overload Is Detected
Two blood tests serve as the initial screen. Transferrin saturation measures how much of your blood’s iron-carrying protein is loaded with iron. Normal levels fall between 20% and 50%. Ferritin, which reflects your body’s total iron stores, normally ranges from 30 to 300 ng/mL. Persistently elevated transferrin saturation (typically above 45%) is the earliest and most sensitive marker. Ferritin rises later as iron accumulates in organs.
If both values are elevated, genetic testing for HFE mutations can confirm whether hereditary hemochromatosis is the cause. Finding two copies of C282Y in someone with high iron markers is generally enough for a diagnosis. In cases where the genetic picture is unclear, a liver biopsy or specialized MRI can measure iron concentration directly.
Secondary Iron Overload
Not all iron overload is genetic. People who receive repeated blood transfusions for conditions like sickle cell disease or certain anemias can accumulate dangerous levels of iron, since the body has no efficient way to excrete it. Chronic liver disease and long-term excessive iron supplementation can also lead to secondary iron overload. These cases are managed differently from hereditary hemochromatosis, but the organ damage from excess iron is the same regardless of the cause.
Secondary hemochromatosis doesn’t have a single prevalence figure because it depends entirely on the underlying condition driving the transfusions or iron accumulation. Among patients with transfusion-dependent blood disorders, iron overload is nearly universal without active management.